Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01225393 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis
A Phase 2 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 2
- Development phase
- 211
- Enrollment target
NCT01225393 is a Phase 2 study that has completed, run by Genentech. The registered enrollment target is 211 participants.
The verdict
NCT01225393, a Phase 2 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 211 participants
- Enrollment target
Study Summary
This is a Phase II, randomized, double-blind, placebo-controlled, parallel-group, multicenter study enrolling patients with active rheumatoid arthritis (RA).
Interventions
- DRUG placebo
- DRUG methotrexate
- DRUG adalimumab
- DRUG leflunomide
- DRUG MLTA3698A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 211 participants |
| Start Date | 2010-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01225393
The ClinicalTrials.gov registry entry for NCT01225393 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 211 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which placebo is the first listed.
NCT01225393 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01225393 about?
NCT01225393 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis". This is a Phase II, randomized, double-blind, placebo-controlled, parallel-group, multicenter study enrolling patients with active rheumatoid arthritis (RA).
What is the current status of trial NCT01225393?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 211 participants. The study started on 2010-11.
What interventions are being tested in trial NCT01225393?
The interventions under investigation include: placebo (DRUG), methotrexate (DRUG), adalimumab (DRUG), leflunomide (DRUG), MLTA3698A (DRUG).
Who is sponsoring clinical trial NCT01225393?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.